Clinical Pharmacokinetics

, Volume 46, Issue 9, pp 787–802 | Cite as

The Absolute Oral Bioavailability and Population-Based Pharmacokinetic Modelling of a Novel Dipeptidylpeptidase-IV Inhibitor, Vildagliptin, in Healthy Volunteers

  • Yan-Ling He
  • Brian M. Sadler
  • Ron Sabo
  • Sebastien Balez
  • Yibin Wang
  • Joelle Campestrini
  • Aziz Laurent
  • Monica Ligueros-Saylan
  • Dan Howard
Original Research Article

Abstract

Background and objective

Vildagliptin is a potent, selective, orally active inhibitor of dipeptidylpeptidase-IV being developed for the treatment of type 2 diabetes mellitus. The objective of this study was to assess the absolute oral bioavailability of vildagliptin by comparing the systemic exposure after oral and intravenous administration in healthy volunteers.

Methods

This was an open-label, randomised, two-period, two-treatment, crossover study in 11 healthy volunteers. Subjects received vildagliptin 50mg orally or 25mg as a 30-minute intravenous infusion on two occasions separated by a 72-hour washout period. Vildagliptin concentrations were determined by a specific assay in urine (lower limit of quantification [LLQ] = 5 ng/mL) and serial plasma samples (LLQ = 2 ng/mL) obtained up to 24 hours after dosing. Noncompartmental analysis and population pharmacokinetic modelling were performed.

Results

Both noncompartmental analysis and population pharmacokinetic modelling estimated the absolute oral bioavailability of vildagliptin to be 85%. Renal elimination of unchanged vildagliptin accounted for 33% and 21% of the administered dose 24 hours after intravenous and oral administration, respectively. Renal clearance (13 L/h) was approximately one-third of the total systemic clearance (41 L/h). Two peaks were observed in plasma concentrations at 1 and 3 hours after oral administration in nine of 11 subjects. Modelling based on the population approach identified two absorption sites with lag-times of 0.225 and 2.46 hours. Both absorption rate constants were slower than the elimination rate constant, indicating ‘flip-flop’ kinetics after oral administration. Bodyweight was identified as a factor with an impact on the volume of distribution of the peripheral compartment. Clearance was 24% greater in males (44.6 L/h) than in females (36.1 L/h).

Conclusions

Vildagliptin is rapidly and well absorbed with an estimated absolute bioavailability of 85%. Two possible sites of absorption were identified, and the absorption rates were slower than the elimination rate, indicating a flip-flop phenomenon after oral dosing.

References

  1. 1.
    Holst JJ, Deacon CF. Inhibition of the activity of dipeptidylpeptidase IV as a treatment for type 2 diabetes. Diabetes 1998 Nov; 47(11): 1663–70PubMedCrossRefGoogle Scholar
  2. 2.
    McIntosh CH, Demuth HU, Pospisilik JA, et al. Dipeptidyl peptidase IV inhibitors: how do they work as new antidiabetic agents? Regul Pept 2005 Jun 15; 128(2): 159–65PubMedCrossRefGoogle Scholar
  3. 3.
    Mest HJ, Mentlein R. Dipeptidyl peptidase inhibitors as new drugs for the treatment of type 2 diabetes. Diabetologia 2005 Apr; 48(4): 616–20PubMedCrossRefGoogle Scholar
  4. 4.
    Kreymann B, Williams G, Ghatei MA, et al. Glucagon-like peptide-1 7–36: a physiological incretin in man. Lancet 1987 Dec 5; 2(8571): 1300–4PubMedCrossRefGoogle Scholar
  5. 5.
    Gutniak M, Orskov C, Holst JJ, et al. Antidiabetogenic effect of glucagon-like peptide-l(7–36) amide in normal subjects and patients with diabetes mellitus. N Engl J Med 1992 May 14; 326(20): 1316–22PubMedCrossRefGoogle Scholar
  6. 6.
    Nathan DM, Schreiber E, Fogel H, et al. Insulinotropic action of glucagonlike peptide-I-(7–37) in diabetic and nondiabetic subjects. Diabetes Care 1992 Feb; 15(2): 270–6PubMedCrossRefGoogle Scholar
  7. 7.
    Nauck MA, Heimesaat MM, Orskov C, et al. Preserved incretin activity of glucagon-like peptide 1 [7–36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 1993 Jan; 91(1): 301–7PubMedCrossRefGoogle Scholar
  8. 8.
    Zander M, Madsbad S, Madsen JL, et al. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 2002 Mar 9; 359(9309): 824–30PubMedCrossRefGoogle Scholar
  9. 9.
    Creutzfeldt WO, Kleine N, Willms B, et al. Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7–36) amide in type I diabetic patients. Diabetes Care 1996 Jun; 19(6): 580–6PubMedCrossRefGoogle Scholar
  10. 10.
    D’Alessio DA, Prigeon RL, Ensinck JW. Enteral enhancement of glucose disposition by both insulin-dependent and insulinindependent processes: a physiological role of glucagon-like peptide I. Diabetes 1995 Dec; 44(12): 1433–7PubMedCrossRefGoogle Scholar
  11. 11.
    Prigeon RL, Quddusi S, Paty B, et al. Suppression of glucose production by GLP-1 independent of islet hormones: a novel extrapancreatic effect. Am J Physiol Endocrinol Metab 2003 Oct; 285(4): E701–7PubMedGoogle Scholar
  12. 12.
    Naslund E, Bogefors J, Skogar S, et al. GLP-1 slows solid gastric emptying and inhibits insulin, glucagon, and PYY release in humans. Am J Physiol 1999 Sep; 277 (3 Pt 2): R910–6PubMedGoogle Scholar
  13. 13.
    Gutzwiller JP, Drewe J, Goke B, et al. Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. Am J Physiol 1999 May; 276 (5 Pt 2): R1541–4PubMedGoogle Scholar
  14. 14.
    Farilla L, Hui H, Bertolotto C, et al. Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. Endocrinology 2002 Nov; 143(11): 4397–408PubMedCrossRefGoogle Scholar
  15. 15.
    Villhauer EB, Brinkman JA, Naderi GB, et al. 1-[[(3-hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. J Med Chem 2003 Jun 19; 46(13): 2774–89PubMedCrossRefGoogle Scholar
  16. 16.
    Dardik B, Valentin M, Schwarztkopf C, et al. NVP-LAF237, a dipeptidyl peptidase IV inhibitor, improves glucose tolerance and delays gastric emptying in obese insulin resistant cynomolgus monkeys [abstract]. Diabetes 2003; 52 Suppl. 1: A322Google Scholar
  17. 17.
    Ahren B, Landin-Olsson M, Jansson PA, et al. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab 2004 May; 89(5): 2078–84PubMedCrossRefGoogle Scholar
  18. 18.
    Edwards CM. The GLP-1 system as a therapeutic target. Ann Med 2005; 37(5): 314–22PubMedCrossRefGoogle Scholar
  19. 19.
    Mari A, Sallas WM, He YL, et al. Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes. J Clin Endocrinol Metab 2005 Aug; 90(8): 4888–94PubMedCrossRefGoogle Scholar
  20. 20.
    He YL, Sabo R, Sunkara G, et al. Evaluation of pharmacokinetic interaction between vildagliptin and digoxin in healthy volunteers. J Clin Pharmacol 2007; 47: 998–1004PubMedCrossRefGoogle Scholar
  21. 21.
    Beal S. NONMEM bug — noninfluential correlated Eta. NONMEM UsersNet Archive 2002 Nov 14 (cited 2006 Nov 13) [online]. Available from URL: http://www.cognigencorp.com/nonmem/nm/99nov142002.html [Accessed 2007 Jul 19]
  22. 22.
    Gillespie WR, Veng-Pedersen P. A polyexponential deconvolution method. Evaluation of the ‘gastrointestinal bioavailability’ and mean in vivo dissolution time of some ibuprofen dosage forms. J Pharmacokinet Biopharm 1985 Jun; 13(3): 289–307PubMedGoogle Scholar
  23. 23.
    Veng-Pedersen P, Gillespie WR. A note on appropriate constraints on the initial input response when applying deconvolution. J Pharmacokinet Biopharm 1986 Aug; 14(4): 441–7PubMedGoogle Scholar
  24. 24.
    Wagner JG. Fundamentals of clinical pharmacokinetics. Hamilton (IL): The Hamilton Press Drug Intelligence Publications, Inc., 1975Google Scholar
  25. 25.
    Prokop EK, Caride VJ, Winchenbach K, et al. Scintigraphic determination of the effect of metoclopramide and morphine on small intestinal transit time. Am J Physiol Imaging 1988; 3(4): 201–4PubMedGoogle Scholar
  26. 26.
    Benmair Y, Fischel B, Frei EH, et al. Evaluation of a magnetic method for the measurement of small intestinal transit time. Am J Gastroenterol 1977 Nov; 68(5): 470–5PubMedGoogle Scholar
  27. 27.
    Scott AM, Kellow JE, Eckersley GM, et al. Cigarette smoking and nicotine delay postprandial mouth-cecum transit time. Dig Dis Sci 1992 Oct; 37(10): 1544–7PubMedCrossRefGoogle Scholar
  28. 28.
    Meier R, Beglinger C, Dederding JP, et al. Influence of age, gender, hormonal status and smoking habits on colonic transit time. Neurogastroenterol Motil 1995 Dec; 7(4): 235–8PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2007

Authors and Affiliations

  • Yan-Ling He
    • 1
  • Brian M. Sadler
    • 2
  • Ron Sabo
    • 3
  • Sebastien Balez
    • 4
  • Yibin Wang
    • 3
  • Joelle Campestrini
    • 4
  • Aziz Laurent
    • 5
  • Monica Ligueros-Saylan
    • 3
  • Dan Howard
    • 3
  1. 1.Exploratory DevelopmentNovartis Institutes for Biomedicai Research, Inc.CambridgeUSA
  2. 2.Strategic PK ConsultingLLCCaryUSA
  3. 3.Novartis PharmaceuticalsEast HanoverNew JerseyUSA
  4. 4.Novartis Pharma SARueil-MalmaisonFrance
  5. 5.PPD Clinical LabAustinUSA

Personalised recommendations